Robert J Aversa

List of Publications by Year
in descending order

11	595	840776 11	1199594 12
papers	citations	h-index	g-index

15	15	15	677
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Continuing Saga of the Marine Polyether Biotoxins. Angewandte Chemie - International Edition, 2008, 47, 7182-7225.	13.8	178
2	Chemical Synthesis of the GHIJKLMNO Ring System of Maitotoxin. Journal of the American Chemical Society, 2008, 130, 7466-7476.	13.7	73
3	Chemical Synthesis of the GHIJK Ring System and Further Experimental Support for the Originally Assigned Structure of Maitotoxin. Angewandte Chemie - International Edition, 2007, 46, 8875-8879.	13.8	71
4	Synthesis of the ABCDEFG Ring System of Maitotoxin. Journal of the American Chemical Society, 2010, 132, 6855-6861.	13.7	62
5	Design and Discovery of N-(2-Methyl-5â€²-morpholino-6â€²-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3â€²-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers. Journal of Medicinal Chemistry, 2017, 60, 4869-4881.	6.4	37
6	Maitotoxin: An Inspiration for Synthesis. Israel Journal of Chemistry, 2011, 51, 359-377.	2.3	33
7	Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 37-41.	2.8	33
8	Synthesis of the Câ€²Dâ€²Eâ€²Fâ€² Domain of Maitotoxin. Journal of the American Chemical Society, 2011, 133, 214-219.	13.7	30
9	Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF. Cancer Research, 2018, 78, 1537-1548.	0.9	30
10	Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic. Journal of Medicinal Chemistry, 2020, 63, 2013-2027.	6.4	27
11	Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 42-46.	2.8	20